White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice

Lancet. 2000 Apr 22;355(9213):1447-53. doi: 10.1016/s0140-6736(00)02150-4.

Abstract

The molecular basis of many leukaemias is now known, allowing precise diagnosis. Treatment of chronic myeloid leukaemia is now possible by targeting of the BCR-ABL tyrosine kinase. The underlying molecular abnormalities in acute leukaemias allow the outlook for individual patients to be assessed at diagnosis and therapy tailored accordingly. Analysis of V(H) genes in B-cell malignant disorders allows these to be placed in the hierarchy of B-cell development and may provide prognostically valuable information.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Chromosome Aberrations / genetics*
  • Chromosome Disorders
  • Chronic Disease
  • Genetic Testing
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / genetics*
  • Hodgkin Disease / therapy
  • Humans
  • Karyotyping
  • Leukemia, Lymphoid / blood
  • Leukemia, Lymphoid / diagnosis
  • Leukemia, Lymphoid / genetics*
  • Leukemia, Lymphoid / therapy
  • Leukemia, Myeloid / blood
  • Leukemia, Myeloid / diagnosis
  • Leukemia, Myeloid / genetics*
  • Leukemia, Myeloid / therapy
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / genetics*
  • Lymphoma, Non-Hodgkin / therapy
  • Molecular Biology*
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / therapy
  • Prognosis